|
Long-Term Debt and Other Financings (Details)
|
3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
USD ($)
|
Mar. 31, 2013
USD ($)
|
Dec. 31, 2013
USD ($)
|
Jan. 31, 2014
Novartis Note [Member]
USD ($)
|
Mar. 31, 2014
Novartis Note [Member]
USD ($)
|
Mar. 31, 2013
Novartis Note [Member]
USD ($)
|
Dec. 31, 2013
Novartis Note [Member]
USD ($)
|
Jan. 31, 2014
Servier Loan [Member]
USD ($)
|
Mar. 31, 2014
Servier Loan [Member]
USD ($)
|
Mar. 31, 2013
Servier Loan [Member]
USD ($)
|
Dec. 31, 2011
Servier Loan [Member]
USD ($)
|
Dec. 31, 2013
Servier Loan [Member]
USD ($)
|
Dec. 31, 2011
Servier Loan [Member]
EUR (€)
|
Mar. 31, 2014
Servier Loan [Member]
Minimum [Member]
|
Mar. 31, 2014
Servier Loan [Member]
Maximum [Member]
|
Sep. 30, 2012
General Electric Capital Corporation Term Loan [Member]
USD ($)
Installment
|
Mar. 31, 2014
General Electric Capital Corporation Term Loan [Member]
USD ($)
Installment
|
Mar. 31, 2013
General Electric Capital Corporation Term Loan [Member]
USD ($)
|
Sep. 27, 2012
General Electric Capital Corporation Term Loan [Member]
USD ($)
|
Dec. 31, 2011
General Electric Capital Corporation Term Loan [Member]
USD ($)
|
Mar. 31, 2014
Other Financings [Member]
USD ($)
|
Mar. 31, 2013
Other Financings [Member]
USD ($)
|
|
| Debt Instrument [Line Items] | ||||||||||||||||||||||
| Maturity date | Jun. 30, 2015 | Jun. 15, 2015 | ||||||||||||||||||||
| Research and development expenses funded through loan facility, maximum (in hundredths) | 75.00% | |||||||||||||||||||||
| Maximum borrowing capacity under loan agreement | $ 50,000,000 | € 15,000,000 | ||||||||||||||||||||
| Variable rate basis | six-month LIBOR | Euro Inter-Bank Offered Rate ("EURIBOR") | ||||||||||||||||||||
| Basis spread on variable rate (in hundredths) | 2.00% | |||||||||||||||||||||
| Interest rate at period end (in hundredths) | 2.35% | |||||||||||||||||||||
| Outstanding principal balance | 9,400,000 | 13,000,000 | 14,800,000 | 20,600,000 | 8,300,000 | 3,100,000 | 10,000,000 | |||||||||||||||
| Percentage of milestone received (in hundredths) | 25.00% | |||||||||||||||||||||
| Milestone received under the collaboration agreement | 7,000,000 | |||||||||||||||||||||
| Repayment of debt | 1,750,000 | |||||||||||||||||||||
| Periodic Payment, Principal | 347,222 | |||||||||||||||||||||
| Proceeds from loan | 19,500,000 | 4,600,000 | ||||||||||||||||||||
| Increase (Decrease) in term loan obligation | 12,500,000 | |||||||||||||||||||||
| Initial interest rate during period (in hundredths) | 3.22% | |||||||||||||||||||||
| Interest rate reset semi-annually during period (in hundredths) | 2.39% | 2.33% | 3.83% | |||||||||||||||||||
| Accrued interest | 1,764,000 | (1,586,000) | 1,900,000 | |||||||||||||||||||
| Unamortized discount on debt | 8,900,000 | |||||||||||||||||||||
| Unrealized foreign exchange gain (loss) | 66,000 | 515,000 | 600,000 | |||||||||||||||||||
| Unrealized foreign exchange loss related to re-measurement of loan discount | 200,000 | |||||||||||||||||||||
| Euro to US Dollar exchange rates | 1.3752 | 1.3766 | ||||||||||||||||||||
| Amortization period for loan discount | 5 years | |||||||||||||||||||||
| Amortization of debt discount | 500,000 | 400,000 | ||||||||||||||||||||
| Carrying value of the loan | 17,000,000 | 16,500,000 | ||||||||||||||||||||
| Recognition of deferred revenue | 500,000 | 400,000 | ||||||||||||||||||||
| Debt issuance costs | 200,000 | 1,300,000 | ||||||||||||||||||||
| Final payment fee | 500,000 | 875,000 | ||||||||||||||||||||
| Fixed interest rate accrued (in hundredths) | 11.71% | 10.90% | ||||||||||||||||||||
| Number of monthly installments | 27 | 42 | ||||||||||||||||||||
| Prepayment premium year one (in hundredths) | 3.00% | |||||||||||||||||||||
| Prepayment premium year two (in hundredths) | 2.00% | |||||||||||||||||||||
| Prepayment premium year thereafter (in hundredths) | 1.00% | |||||||||||||||||||||
| Aggregate number of unregistered shares of common stock called by warrants (in shares) | 263,158 | 39,346 | ||||||||||||||||||||
| Warrants exercise price (in dollars per share) | $ 1.14 | $ 3.54 | ||||||||||||||||||||
| Immediate Term for warrants exercisable (in years) | 5 years | 5 years | ||||||||||||||||||||
| Fair value of warrant liability | 200,000 | 100,000 | ||||||||||||||||||||
| Interest expense and amortization of debt issuance costs [Abstract] | ||||||||||||||||||||||
| Interest expense | $ 1,125,000 | $ 1,172,000 | $ 77,000 | $ 91,000 | $ 587,000 | $ 525,000 | $ 448,000 | $ 545,000 | $ 13,000 | $ 11,000 | ||||||||||||